Liberty Street Advisors Inc. Decreases Stock Holdings in Omada Health, Inc. $OMDA

Liberty Street Advisors Inc. lessened its stake in Omada Health, Inc. (NASDAQ:OMDA) by 43.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 125,050 shares of the company’s stock after selling 94,750 shares during the quarter. Omada Health comprises 3.8% of Liberty Street Advisors Inc.’s investment portfolio, making the stock its 4th biggest position. Liberty Street Advisors Inc.’s holdings in Omada Health were worth $1,572,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of OMDA. Bank of New York Mellon Corp increased its holdings in Omada Health by 284.5% in the 1st quarter. Bank of New York Mellon Corp now owns 75,681 shares of the company’s stock valued at $951,000 after buying an additional 55,996 shares during the period. Fifth Third Bancorp bought a new stake in shares of Omada Health during the 1st quarter worth approximately $127,000. Inspire Investing LLC lifted its holdings in shares of Omada Health by 35.5% during the 1st quarter. Inspire Investing LLC now owns 40,462 shares of the company’s stock worth $509,000 after acquiring an additional 10,591 shares during the period. SG Americas Securities LLC acquired a new stake in shares of Omada Health during the 1st quarter worth approximately $10,401,000. Finally, XTX Topco Ltd bought a new position in Omada Health in the fourth quarter valued at approximately $297,000.

Omada Health Price Performance

Shares of OMDA opened at $23.70 on Monday. The stock has a market cap of $1.41 billion and a PE ratio of -87.78. Omada Health, Inc. has a 12-month low of $10.28 and a 12-month high of $26.92. The business has a 50-day simple moving average of $19.01 and a two-hundred day simple moving average of $15.66.

Omada Health (NASDAQ:OMDA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. The firm had revenue of $78.05 million for the quarter. Omada Health had a negative return on equity of 1.82% and a negative net margin of 2.22%. On average, equities research analysts expect that Omada Health, Inc. will post -0.01 EPS for the current year.

Insider Activity at Omada Health

In other Omada Health news, CFO Steven L. Cook sold 33,000 shares of the business’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $19.89, for a total transaction of $656,370.00. Following the sale, the chief financial officer directly owned 133,359 shares of the company’s stock, valued at $2,652,510.51. The trade was a 19.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Craig Gracey sold 6,894 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $17.42, for a total transaction of $120,093.48. Following the completion of the transaction, the chief accounting officer owned 9,191 shares of the company’s stock, valued at approximately $160,107.22. This trade represents a 42.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 193,462 shares of company stock worth $3,927,425 in the last quarter. 6.38% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on OMDA shares. BTIG Research started coverage on Omada Health in a research note on Friday. They set a “buy” rating and a $30.00 target price for the company. The Goldman Sachs Group reiterated a “buy” rating on shares of Omada Health in a research note on Friday, May 8th. Canaccord Genuity Group set a $24.00 price target on Omada Health in a report on Friday, May 8th. Morgan Stanley reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of Omada Health in a research note on Monday, June 22nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of Omada Health in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $23.50.

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.